EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022
In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 month...
Source: sina.com.hk